CHICAGO, Jan 30 (Reuters) - Novo Nordisk on Tuesday said U.S. regulators boosted its approval rating on its insulin injection, indicating it is safe for pregnant women with Type 1 diabetes to use.
The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar product referencing Novo Nordisk A/S’ Novolog (insulin aspart), a ...
Kirsty 100units/mL is supplied as a 3mL single-patient-use prefilled pen as well as a 10mL multiple-dose vial. The approval of insulin aspart-xjhz was supported by a comprehensive data package that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results